21 results
Thumbnail

D2.413 - Diagnostic Value of the Basophil Degranulation Test in High-Risk Drug-Induced Anaphylaxis

Thumbnail

D2.415 - DRESS Syndrome induced by Lenalidomide

Thumbnail

D2.407 - Treating Through in Pediatric Patients: A Single-Center Experience

Thumbnail

D2.408 - Hypersensitivity Reactions to Corticosteroids: A Retrospective Cohort Study

Thumbnail

D2.414 - Diagnostic Distribution of Patch, Delayed-Reading Intradermal, and Drug Provocation Tests in Delayed-Type Cutaneous Drug Hypersensitivity

Thumbnail

D2.416 - Skin reaction to Kaftrio/Kalydeco (CFTR) in cystic fibrosis: safe reintroduction using an outpatient desensitization protocol

Thumbnail

D2.418 - Tolperisone Hypersensitivity: An Underrecognized Drug Allergy in the Context of Widespread Off-Label Use

Thumbnail

D2.419 - DRESS syndrome in the context of carbamazepine treatment - case report

Thumbnail

D2.420 - A challenging case of cardiotoxicity following palbociclib therapy

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort

Thumbnail

D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants

Thumbnail

D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut